Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Market Cap: US$15.6b

Teva Pharmaceutical Industries Management

Management criteria checks 4/4

Teva Pharmaceutical Industries' CEO is Richard Francis, appointed in Jan 2023, has a tenure of 2.25 years. total yearly compensation is $15.52M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $3.70M. The average tenure of the management team and the board of directors is 2.5 years and 7.8 years respectively.

Key information

Richard Francis

Chief executive officer

US$15.5m

Total compensation

CEO salary percentage10.3%
CEO tenure2.3yrs
CEO ownership0.02%
Management average tenure2.5yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Teva Pharmaceutical: A Risky Bet With Potential Upside

Feb 28

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Feb 27
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Jan 30

There's No Escaping Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Muted Revenues Despite A 27% Share Price Rise

Jan 12
There's No Escaping Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Muted Revenues Despite A 27% Share Price Rise

Duvakitug And Teva's Growth: A Game Changer In Pharma

Dec 27

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Dec 04

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

CEO Compensation Analysis

How has Richard Francis's remuneration changed compared to Teva Pharmaceutical Industries's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$16mUS$2m

-US$2b

Sep 30 2024n/an/a

-US$959m

Jun 30 2024n/an/a

-US$453m

Mar 31 2024n/an/a

-US$478m

Dec 31 2023US$26mUS$2m

-US$559m

Compensation vs Market: Richard's total compensation ($USD15.52M) is about average for companies of similar size in the US market ($USD14.30M).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.


CEO

Richard Francis (56 yo)

2.3yrs

Tenure

US$15,518,947

Compensation

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...


Leadership Team

NamePositionTenureCompensationOwnership
Richard Francis
President2.3yrsUS$15.52m0.024%
$ 3.7m
Eliyahu Kalif
Executive VP & CFO5.3yrsUS$6.18m0.040%
$ 6.2m
Richard Daniell
Executive Vice President of European Commercial7.4yrsUS$5.43m0.0042%
$ 657.6k
Eric Hughes
Executive VP of Global R&D and Chief Medical Officer2.7yrsUS$5.75mno data
Christine Fox
Executive VP of U.S. Commercial Business1.4yrsUS$5.22m0.0051%
$ 794.8k
Matthew Shields
Executive Vice President of Global Operationsless than a yearno datano data
Amir Weiss
Senior VP & Chief Accounting Officer3.4yrsno data0.0026%
$ 411.4k
Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligenceno datano datano data
Kathleen Veit
Senior Vice President2.8yrsno datano data
David Mcavoy
Executive VP & Chief Legal Officer1.1yrsno data0.0010%
$ 162.1k
Placid Jover
Executive VP & CHROless than a yearno datano data
Kevin Mannix
Senior Vice President of Investor Relationsno datano datano data

2.5yrs

Average Tenure

53yo

Average Age

Experienced Management: TEVA's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Francis
Presidentno dataUS$15.52m0.024%
$ 3.7m
Sol Barer
Independent Chairman of the Board10.3yrsUS$539.99k0.036%
$ 5.6m
Amir Elstein
Independent Director16.3yrsUS$339.99k0.18%
$ 28.5m
Gerald Lieberman
Independent Director9.6yrsUS$354.99k0.0092%
$ 1.4m
Roberto Mignone
Independent Director7.8yrsUS$339.99k0.0083%
$ 1.3m
Rosemary Crane
Independent Director9.6yrsUS$329.99k0.0090%
$ 1.4m
Janet Vergis
Independent Director4.8yrsUS$334.99k0.0056%
$ 871.1k
Chen Lichtenstein
Independent Directorless than a yearUS$93.32kno data
Tal Zaks
Independent Director3.5yrsUS$329.99k0.0043%
$ 668.5k
Perry Nisen
Independent Director7.8yrsUS$334.99k0.0083%
$ 1.3m
Ronit Satchi-Fainaro
Independent Director6.8yrsUS$319.99k0.0077%
$ 1.2m
Varda Shalev
Independent Director1.6yrsUS$309.99k0.0011%
$ 174.5k

7.8yrs

Average Tenure

62yo

Average Age

Experienced Board: TEVA's board of directors are considered experienced (7.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/16 11:42
End of Day Share Price 2025/04/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Teva Pharmaceutical Industries Limited is covered by 58 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Richard SilverBarclays
Balaji PrasadBarclays